Ryuichi Kiyama - Shionogi Executive Officer

All Insiders . USA . 
Stock . Shionogi Co . Stakeholders . Insider . Ryuichi Kiyama
SGIOF Stock  USD 14.10  1.69  13.62%   

Executive

Ryuichi Kiyama is Executive Officer of Shionogi Co
Phone81 6 6202 2161
Webhttps://www.shionogi.com

Shionogi Management Efficiency

The company has return on total asset (ROA) of 0.1067 % which means that it generated a profit of $0.1067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2014 %, meaning that it generated $0.2014 on every $100 dollars invested by stockholders. Shionogi's management efficiency ratios could be used to measure how well Shionogi manages its routine affairs as well as how well it operates its assets and liabilities.
Shionogi Co has accumulated 6.65 B in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Shionogi has a current ratio of 5.16, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Shionogi until it has trouble settling it off, either with new capital or with free cash flow. So, Shionogi's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Shionogi sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Shionogi to invest in growth at high rates of return. When we think about Shionogi's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Ronald SilverIronwood Pharmaceuticals
41
Debra WilsonAurora Cannabis
N/A
Jonathan PageAurora Cannabis
55
Mike NanfitoIronwood Pharmaceuticals
N/A
Darryl VleemingAurora Cannabis
N/A
Kristen JDPacira BioSciences,
50
Dennis McLoughlinPacira BioSciences,
58
Allan CleirenAurora Cannabis
N/A
Jaclyn JaffeJourney Medical Corp
N/A
Eric BenevichNeurocrine Biosciences
59
Jillian SwainsonAurora Cannabis
N/A
Dave AirdAurora Cannabis
N/A
Alex MillerAurora Cannabis
N/A
Charles LaranjeiraPacira BioSciences,
58
Michelle LeflerAurora Cannabis
N/A
Tiffany MBAEsperion Therapeutics
N/A
Jane SorensenNeurocrine Biosciences
N/A
Ingrid DelaetNeurocrine Biosciences
58
Paul SchwichtenbergAssertio Therapeutics
53
Christopher YoungPacira BioSciences,
52
DO EllisPacira BioSciences,
53
Shionogi Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Shionogi Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan. Shionogi operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5693 people. Shionogi Co [SGIOF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity0.2
Return On Asset0.11

Shionogi Leadership Team

Elected by the shareholders, the Shionogi's board of directors comprises two types of representatives: Shionogi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shionogi. The board's role is to monitor Shionogi's management team and ensure that shareholders' interests are well served. Shionogi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shionogi's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kohji Hanasaki, Sr Division
Isao Teshirogi, CEO and President and Representative Director
Kazuhiro Hatanaka, Executive Officer
Ryuichi Kiyama, Executive Officer
Yoshihiro Furuya, VP Office
John Keller, Executive Officer
Takeshi Shiota, Executive Officer
Akira Kato, Executive Officer
Susumu Mitsumori, VP Department
Yoshimasa Kyokawa, VP Office

Shionogi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Shionogi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.2
Return On Asset0.11
Profit Margin0.44 %
Operating Margin0.43 %
Current Valuation11.39 B
Shares Outstanding298.16 M
Shares Owned By Insiders4.66 %
Shares Owned By Institutions52.78 %
Price To Earning15.47 X
Price To Book2.01 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Shionogi Pink Sheet

Shionogi financial ratios help investors to determine whether Shionogi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shionogi with respect to the benefits of owning Shionogi security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY